Literature DB >> 19560219

DNA repair in TUNEL-positive atrial cardiomyocytes of mitral and tricuspid valve diseases: potential mechanism for preserving cardiomyocytes.

Jen-Ping Chang1, Mien-Cheng Chen, Wan-Ying Lin, Wen-Hao Liu, Chien-Jen Chen, Yung-Lung Chen, Kuo-Li Pan, Tzu-Hsien Tsai, Hsueh-Wen Chang.   

Abstract

BACKGROUND: The reported presence of DNA breaks, based on a positive reaction to the terminal deoxynucleotidyl transferase (TdT)-mediated dUTP in situ nick end-labelling (TUNEL) assay, in fibrillating human right atria of cardiac valve disease may suggest apoptotic myocyte death. However, TUNEL positivity may reflect conditions other than cell death.
METHODS: This study comprised 27 adult patients (14 patients with persistent atrial fibrillation and 13 in sinus rhythm) with significant mitral and tricuspid valve diseases. Atrial tissues were obtained during surgery.
RESULTS: Immunohistochemical study demonstrated that 31.1±12.2% of the myocytes had TUNEL-positive nuclei in the fibrillating right atria whereas 37.4±23.2% of the myocytes had TUNEL-positive nuclei in the right atrial myocardium in sinus rhythm (p=0.505). However, most nuclei of TUNEL-positive myocytes in the right atria also expressed proliferating cell nuclear antigen (PCNA), an indicator of DNA replication and repair but never Ki-67, a replication-associated antigen (TUNEL(+)/PCNA(+) vs. TUNEL(+)/PCNA(-), 30.5±10.8% vs. 1.2±1.5%, p=0.005, in the atrial fibrillation group and 32.8±18.6% vs. 4.6±8.1%, p=0.003, in the sinus group), suggesting that most TUNEL-positive myocytes were undergoing DNA repair. In addition, the incidence of TUNEL-positive myocytes significantly and positively correlated with the incidence of PCNA-positive myocytes (r=0.5, p<0.03 in the right atria; r=0.661, p<0.04 in the left atria).
CONCLUSIONS: Cell death by apoptosis occurs in a small percentage of atrial cardiomyocytes in mitral and tricuspid valve diseases and DNA repair is more important and preserves the cardiomyocytes.
Copyright © 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19560219     DOI: 10.1016/j.ijcard.2009.06.012

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Enhanced expression of ROCK in left atrial myocytes of mitral regurgitation: a potential mechanism of myolysis.

Authors:  Huang-Chung Chen; Jen-Ping Chang; Tzu-Hao Chang; Yu-Sheng Lin; Yao-Kuang Huang; Kuo-Li Pan; Chih-Yuan Fang; Chien-Jen Chen; Wan-Chun Ho; Mien-Cheng Chen
Journal:  BMC Cardiovasc Disord       Date:  2015-05-09       Impact factor: 2.298

2.  Exploring Regulatory Mechanisms of Atrial Myocyte Hypertrophy of Mitral Regurgitation through Gene Expression Profiling Analysis: Role of NFAT in Cardiac Hypertrophy.

Authors:  Tzu-Hao Chang; Mien-Cheng Chen; Jen-Ping Chang; Hsien-Da Huang; Wan-Chun Ho; Yu-Sheng Lin; Kuo-Li Pan; Yao-Kuang Huang; Wen-Hao Liu; Chia-Chen Wu
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

3.  Differential Gene Expression Profile of Renin-Angiotensin System in the Left Atrium in Mitral Regurgitation Patients.

Authors:  Wen-Hao Liu; Yen-Nan Fang; Chia-Chen Wu; Mien-Cheng Chen; Jen-Ping Chang; Yu-Sheng Lin; Kuo-Li Pan; Wan-Chun Ho; Tzu-Hao Chang; Yao-Kuang Huang; Chih-Yuan Fang; Chien-Jen Chen; Wei-Chieh Lee
Journal:  Dis Markers       Date:  2018-11-18       Impact factor: 3.434

4.  Effect of different cardioprotective methods on extracorporeal circulation in fetal sheep: a randomized controlled trial.

Authors:  Yi-Bo Yan; Shuo Shi; Qian-Biao Wu; Jin-Sheng Cai; Bin-Feng Lei
Journal:  J Cardiothorac Surg       Date:  2021-04-17       Impact factor: 1.637

5.  Deciphering the gene expression profile of peroxisome proliferator-activated receptor signaling pathway in the left atria of patients with mitral regurgitation.

Authors:  Mien-Cheng Chen; Jen-Ping Chang; Yu-Sheng Lin; Kuo-Li Pan; Wan-Chun Ho; Wen-Hao Liu; Tzu-Hao Chang; Yao-Kuang Huang; Chih-Yuan Fang; Chien-Jen Chen
Journal:  J Transl Med       Date:  2016-06-02       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.